Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase 1 CaDAnCe-101 study Meeting Abstract
| Authors: | Thompson, M. C.; Parrondo, R. D.; Frustaci, A. M.; Allan, J. N.; Ghia, P.; Mocanu, I.; Tam, C. S.; Trotman, J.; Ahn, I. E.; Stilgenbauer, S.; Scarfo, L.; Chen, X.; By, K.; Fabre, S.; Persky, D. O.; Agarwal, A.; Seymour, J. F. |
| Abstract Title: | Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase 1 CaDAnCe-101 study |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 885 |
| End Page: | 886 |
| Language: | English |
| ACCESSION: | WOS:001412804100029 |
| DOI: | 10.1182/blood-2024-199116 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
